Source:
[ Ссылка ]
Cancer is one therapeutic area where patients cannot wait the conventional 10 or 12 years for a new therapy. For these patients, time is of the essence, and improved access to faster clinical trials can be the difference between receiving a new life-saving medicine and it being too late.
In this episode, we talk to David Raben, vice president of Global Development Oncology at Amgen, about the next generation of oncology trial design and execution.
To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.
Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.
